Marios Panagiotou (National and Kapodistrian University of Athens, Athens, Greece) discusses the background and findings of his late-breaking presentation entitled: Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy.
Questions
1. What treatment response criteria have been used in previous studies of anti-interleukin-5 (IL-5) antibodies in patients with severe eosinophilic asthma? (0:12)
2. Why was daily physical activity (DLA) chosen as a clinical endpoint in your recent study? (0:47)
3. Could you tell us a little about the study design and how DLA was measured? (1:52)
4. What have been the preliminary findings of this study? (3:12)
5. What further studies are planned? (4:39)
Speaker disclosure: Marios Panagiotou has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
